Impact of Nutritional Management on the Frailty of Patients Waiting for Liver Transplantation (Via the LFI Tool)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorHospices Civils de Lyon

About this trial

Cirrhosis is a major public health issue responsible for about 15000 deaths each year. Liver transplantation (LT) remains the only curative treatment for decompensated cirrhosis. Decompensated cirrhotic patients awaiting LT are malnourished, sarcopenic and fragile. The evaluation of the nutritional status of these patients is complex because the anthropometric data that define undernutrition (weight variation, BMI) are often compromised by the presence of edema and ascites related to liver disease. It therefore seems appropriate to focus on the fragility and sarcopenia of the cirrhotic patient as a reflection of the nutritional status. In 2017, the American team of Lai et al. validated a Liver fraily index (LFI) score of frailty specific to cirrhotic patients waiting for LT. The LFI is composed of three simple physical tests (Grip test, chair lift test, and balance tests) performed at the patient's bedside, which results in a quantitative and reproducible frailty score. Frailty while waiting for LT is associated with an increase in mortality on the waiting list, independently of the MELD (Model for End stage Liver disease) score, which is a reflection of liver severity. About half of the patients who are candidates for LT will present an aggravation of their frailty while waiting for LT. To date, no study has reported the results of a nutritional intervention on the evolution of fragility in patients awaiting LT. The objective of our study is to evaluate the impact of a nutritional management and follow-up by a dietitian specialized in hepatology on the fragility of patients waiting for LT. This is a monocentric study, randomized in two parallel groups (an intervention group with nutritional follow-ups by a trained dietitian and a control group with follow-up by the reference hepatologist without specific dietary management by a dietician) in open. All patients enrolled on the LT list with an LFI \> 3.2 (pre-frail and frail state) will be included in the study. It is planned to include 210 patients over a period of 24 months. The LFI will be measured for all patients (control group + intervention group) at 3 and 6 months, as part of their follow-up in the LT center. This study will also make it possible to correlate frailty with other parameters (severity of liver disease, access to LT).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient aged ≥ 18 years

Patient registered on the waiting list for Hepatic Transplantation in the Transplantation center of the Croix Rousse Hospital (GHN), Hospices Civils de Lyon

Dated and signed an informed consent

Affiliated to a social security scheme or beneficiary of a similar scheme

Disqualifiers

Patient hospitalized in intensive care

Patient with initial LFI test result < to 3.2, that is considered as "robust".

Patient unable to perform LFI exercises (chronic or acute motor disability in lower or upper limbs)

Pregnant, parturient or lactating women

Trial design

Design model

Parallel

Treatments tested in this trial

  • Dietary management

    Dietary supplement

    The intervention consists of a personalized dietary management with a nutritional follow-up pending transplantation. Teleconsultation appointments are scheduled with the dietician for dietary coaching and a re-evaluation of the nutritional strategy every month. Follow-up visits in person, carried out by the dietitian at the 3rd and 6th month waiting for transplant and are coupled with the usual consultations with the referring hepatologist. The visits allow the realization of LFI (Liver Frailty Index), the collection of interrelated events and the reassessment of hepatic disease as well as the re-evaluation of the nutritional strategy (CNO, enteral or parenteral nutrition)

  • No dietary management

    Other intervention

    The patient will be followed up by his reference hepatologist every 3 months. Follow-up visits at 3 months and 6 months waiting for liver transplantation will be performed by Clinical Research assistant on the same day as the follow-up consultation with his hepatologist with the completion of the Liver Frailty Index test and the collection of intercurrent events and the reassessment of liver disease.

Treatment groups

210 Participants
are divided into 2 treatment groups
Group A: Dietary intervention GroupExperimental treatment 1 intervention
Group B: Standard Follow upOther 1 intervention

Trial outcomes

Primary outcomes

1

Evaluate the impact at 3 months, of a nutritional management and follow-up by a dietitian specialized in hepatology compared to the usual management without dietary follow-up, on the fragility of patients waiting for liver transplantation (LT).

Measurement of LFI (Liver fraily index) score score variation between D0 (baseline = visit 1) and 3 months (first reassessment = visit 2) during the liver transplantation waiting period. This variation will be compared between the intervention group and the control group.

Time frame
3rd month after visit 1.

Secondary outcomes

1

Evaluate the impact of a nutritional follow-up on the fragility of patients at 6 months on list

For patients still on the liver transplantation waiting list, comparison between the intervention and control group of the LFI (Liver fraily index) variation between Baseline (visit 1) and month 6 (visit 3).

Time frame
6th Month after visit 1.
2

Evaluate the impact of a nutritional follow-up on the distribution of patients' frailty according to classes: robust, pre-fragile, fragile

Compare the evolution of the fragility profile (Robust - Prefragile - Fragile) of patients waiting for liver transplantation according to LFI (Liver fraily index) at M3 and M6 in the intervention group and in the control, group compared with the initial LFI (D0)

Time frame
3rd Month (M3) after Visit 1 and M6 after V1
3

Evaluate compliance with oral nutritional supplement treatment for patients awaiting transplant

At each follow-up visit (M3 and M6) assessment of compliance with oral nutritional supplements for patients who were prescribed oral nutritional supplements, through questioning their intake: 0, 1⁄4, 1⁄2, 3⁄4 or all of the oral nutritional supplements consumed compared to the prescription.

Time frame
3rd Month and 6th month after Visit 1
4

Evaluate the relationship between fragility and severity of liver disease (MELD score)

Measure the correlation between LFI (Liver fraily index) at Day 0, M3 and M6 and the severity of liver disease (MELD score),

Time frame
Day 0, 3rd Month (M3) and 6th Month (M6)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.